BioPharmSignal logoBioPharmSignal

Biotech News

CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy

CVRx (CVRX)CVRxCommercial

MINNEAPOLIS, Aug. 24, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Devoted Health

Related news

CVRXCVRx2026-08-11 11:00 EST

CVRx Announces Sales Leadership Transition

CVRXCVRx2026-06-09 11:30 EST

CVRx Announces Chief Financial Officer Transition

RYTMRhythm Pharmaceuticals2026-08-17 12:00 EST

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

RYTMRhythm Pharmaceuticals2026-08-04 20:01 EST

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

IARTIntegra LifeSciences2026-06-23 12:00 EST

Integra LifeSciences Announces Key Executive Appointments

ICCMIceCure Medical2026-07-14 12:32 EST

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

HYPRHyperfine2026-07-01 12:15 EST

Hyperfine Announces European Launch of Next-Generation Swoop® System

SGHTSight Sciences2026-08-05 20:04 EST

Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems

XAIRBeyond Air2026-08-04 12:00 EST

Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026

STIMNeuronetics2026-07-28 12:32 EST

Greenbrook Opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, Maryland

View all latest news

CVRx

Cardiovascular Neuromodulation CVRx is a commercial-stage medical-device company focused on neuromodulation therapies for cardiovascular disease. Its technology electrically activates the body's baroreflex to influence autonomic pathways involved in heart-failure progression. Barostim Platform Barostim is the company's implantable...

Recent company news

CVRXCVRx2026-08-24 12:30 EST

CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy

CVRXCVRx2026-08-11 11:00 EST

CVRx Announces Sales Leadership Transition

CVRXCVRx2026-08-06 20:05 EST

CVRx Reports Second Quarter 2026 Financial and Operating Results

CVRXCVRx2026-07-28 12:30 EST

CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference

CVRXCVRx2026-07-23 20:30 EST

CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026

Stock data

Close
2.84 USD
Market cap
144.09M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States